Compounded does not mean FDA-approved

FDA's April 2026 reminder

In an update dated April 1, 2026, FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under federal law.

For section 503A, FDA describes compounding for an individual patient based on a prescription and restrictions on regularly making drugs that are essentially copies of commercially available products. The guidance also describes a prescriber-documented change that produces a significant difference for an identified individual patient.

That is not a blanket permission to offer compounded versions to everyone. The full guidance and the circumstances matter.

Approval is a separate question

FDA states that compounded drugs are not FDA-approved. The agency does not verify their safety, effectiveness or quality before they are marketed.

FDA also warns about products marketed as "research purposes" or "not for human consumption" while being sold for human use. Those words are not a substitute for an approved medicine or a lawful prescription pathway.

For clinic owners

Keep regulatory review separate from a supplier-price comparison. Ask a licensed pharmacist or prescriber to review the exact preparation and applicable requirements before making a clinical or purchasing decision. A price comparison does not establish clinical suitability or regulatory eligibility.